Korean J Med.  2009 Dec;77(6):686-694.

An update on new drugs for diabetic nephropathy

Affiliations
  • 1Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea.

Abstract

Prevention, early detection, and treatment of renal disease in diabetic patients are becoming major healthcare issues. It is well known that hyperglycemia is a major risk factor for the development and progression of diabetic nephropathy. Therapeutic options such as strict glycemic control and early antihypertensive treatment effectively prevent or slow the progression of renal disease in both types of diabetes, depending on the clinical manifestations. The mainstay of diabetic nephropathy therapy is good glycemic control and maintaining optimal blood pressure with angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs). Additionally, correction of dyslipidemia and cessation of smoking are additional important factors to prevent and slow the progression of diabetic nephropathy. Biochemical and hemodynamic hypotheses have been proposed and are supported by animal models as the principal causes of the development and progression of diabetic nephropathy. This review discusses new insights into the recent trend focusing on new therapies, including hemodynamic agents and biochemical agents for preventing and delaying the progression of diabetic nephropathy.

Keyword

Diabetic nephropathy; Therapy

MeSH Terms

Angiotensin Receptor Antagonists
Blood Pressure
Delivery of Health Care
Diabetic Nephropathies
Dyslipidemias
Hemodynamics
Humans
Hyperglycemia
Models, Animal
Peptidyl-Dipeptidase A
Risk Factors
Smoke
Smoking
Angiotensin Receptor Antagonists
Peptidyl-Dipeptidase A
Smoke
Full Text Links
  • KJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr